Search

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES (EP3244930A1)

The European Patent Office granted patent EP3244930A1 to the University of Southern California covering pharmaceutical compositions comprising POH derivatives with anti-cancer properties. The patent names Thomas Chen, Daniel Levin, and Satish G. Pupalli as inventors. The patent is classified under A61P 35/00 (antineoplastic agents) and designates all European member states including DE, FR, GB, IT, ES, and NL.

Recombinant Protein UK114 in Stable Polymer Form for Solid and Systemic Tumour Treatment

The European Patent Office has published patent application EP3554639A1 filed by Alberto Bartorelli Cusani for a recombinant protein UK114 in stable polymer form for use in treating or preventing malignant solid and systemic tumours. The application is classified under IPC codes A61K and A61P covering therapeutic preparations. The patent has been designated across all European Patent Convention member states.

Process for Preparing Cannabinoid-Containing Oral Pharmaceutical Composition

The European Patent Office granted Patent EP3351242A1 to Prati, Donaduzzi & Cia LTDA and Universidade De São Paulo for a process preparing a cannabinoid-containing oral pharmaceutical composition. The patent covers compositions for treating neurological and psychiatric conditions including seizures, Parkinson's disease, and anxiety disorders. The oral formulation can be delivered as a liquid, softgel, or powder.

Therapeutic Combinations Comprising Anti-FOLR1 Immunoconjugates

EPO published patent application EP3349796A1 for ImmunoGen, Inc., covering therapeutic combinations of anti-FOLR1 immunoconjugates for cancer treatment. The A1 publication indicates the application has passed EPO's search examination and is now publicly available. The patent covers compositions including the novel ADC candidate targeting folate receptor alpha (FOLR1), a validated cancer antigen, along with combination therapies using cytotoxins and additional anticancer agents.

Carbon Dots for Diagnostic Analysis and Drug Delivery (EP3411330A1)

The EPO published patent application EP3411330A1 for carbon dot compositions and methods for diagnostic analysis and drug delivery. The patent was filed by inventors from the University of Miami. The designated states cover most European countries including DE, FR, GB, IT, ES, NL, BE, and others.

Artificial Nucleosides, Nucleotides, Therapeutic Applications (EP3418289A1)

The European Patent Office published patent application EP3418289A1, filed by Institute of Science Tokyo and Nissan Chemical Corporation, covering artificial nucleosides, nucleotides, and artificial oligonucleotides with therapeutic applications. The application (A1 publication with search report) was published on April 8, 2026, and designates 31 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Sudan Crisis, 4M Malnourished, 37% Health Facilities Closed

WHO reports that three years of conflict in Sudan have created the world's largest humanitarian and displacement crisis. Nearly 4 million people are estimated to be acutely malnourished in 2026, with disease outbreaks including malaria, dengue, measles, and polio spreading across multiple states. Some 37% of health facilities across Sudan's 18 states remain non-functional, while WHO has verified 217 attacks on health care since April 2023.

Safety Assessment of Genome Editing Human Gene Therapy Products Using Next-Generation Sequencing

FDA's Center for Biologics Evaluation and Research has issued draft guidance recommending next-generation sequencing (NGS)-based methods for assessing safety of human genome editing gene therapy products in nonclinical studies. The guidance addresses evaluation of off-target editing risks and genome integrity for products supporting IND and BLA applications. Comments are being accepted via regulations.gov under docket FDA-2026-D-1255.

Peptide Amide Composition for Kappa Opioid Receptor Treatment

USPTO granted Patent US12599647B2 to Xizang Haisco Pharmaceutical Co., Ltd. for a peptide amide composition containing a compound of formula (I) and pH regulators (pH 3-5.5). The composition is designed for treating or preventing diseases or conditions associated with kappa opioid receptors. The patent includes 19 claims and covers the compound composition, preparation methods, and medical applications.

Nestlé Granted Patent for Green Coffee Insulin Treatment Composition

USPTO granted Patent US12599643B2 to Societe des Produits Nestle S.A. for green coffee-based compositions comprising hydrolysed chlorogenic acid for improving insulin profile. The patent covers compositions for treating or preventing disorders linked to increased plasma postprandial insulin, including esterase treated decaffeinated green coffee extract with 40-200 mg daily dosage. The patent contains 16 claims and was filed March 27, 2020.